Emergent Factory Halt Adds to Obstacles for J&J’s Covid Vaccine

April 19, 2021, 10:19 PM

Emergent BioSolutions Inc. was told by U.S. regulators to stop making Johnson & Johnson’s Covid-19 vaccine at a facility where 15 million doses worth of a key ingredient had to be discarded, adding to roadblocks preventing wider use the single-dose shot.

Use of J&J’s vaccine has been paused since last week as health officials probe a possible link to life-threatening blood clots. The halt at Emergent, a contract manufacturer, could add to questions about how many Americans will ultimately receive J&J’s shot even if it is found to be safe.

On April 12, the U.S. Food and Drug Administration ...

To read the full article log in.

Learn more about a Bloomberg Law subscription